In 2005, the first long-acting GLP-1 receptor agonist compound (exenatide) was approved for the treatment of T2D by the Food and Drug Administration (FDA), and a total of 5 GLP1-receptor agonist agents are approved in the US as of 2023 (lixisenatide, liraglutide, dulaglutide, two versions of exenatide and 3 versions of semaglutide). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.